Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Histone deacetylases and cancer: causes and therapies
20011.6k citationsPaul A. Marks, Richard A. Rifkind et al.profile →
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
19991.4k citationsVictoria M. Richon, Richard A. Rifkind et al.profile →
Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells
20001.0k citationsP A Marks, Victoria M. Richon et al.profile →
2000521 citationsLisa M. Butler, Howard I. Scher et al.PubMedprofile →
Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas
2010500 citationsChristopher J. Sneeringer, Margaret Porter Scott et al.Proceedings of the National Academy of Sciencesprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
Countries citing papers authored by Victoria M. Richon
Since
Specialization
Citations
This map shows the geographic impact of Victoria M. Richon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Victoria M. Richon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Victoria M. Richon more than expected).
Fields of papers citing papers by Victoria M. Richon
This network shows the impact of papers produced by Victoria M. Richon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Victoria M. Richon. The network helps show where Victoria M. Richon may publish in the future.
Co-authorship network of co-authors of Victoria M. Richon
This figure shows the co-authorship network connecting the top 25 collaborators of Victoria M. Richon.
A scholar is included among the top collaborators of Victoria M. Richon based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Victoria M. Richon. Victoria M. Richon is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Daigle, Scott R., Edward J. Olhava, Aravind Basavapathruni, et al.. (2013). Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood. 122(6). 1017–1025.546 indexed citations breakdown →
Sneeringer, Christopher J., Margaret Porter Scott, Kevin W. Kuntz, et al.. (2010). Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proceedings of the National Academy of Sciences. 107(49). 20980–20985.500 indexed citations breakdown →
Roth, Jennifer A., Susan Korenchuk, Theresa Zhang, et al.. (2007). Mechanisms of in vitro acquired resistance to vorinostat (suberoylanilide hydroxamic acid, SAHA). Cancer Research. 67. 694–694.3 indexed citations
10.
Ginanni, Nicole, Yanai Zhan, Michael R. Tota, et al.. (2007). Kinetic analysis of the fatty acid synthesis pathway in HCT-116 colon cancer cells: role of FAS and ACC1 in maintaining tumor cell viability and proliferation. Cancer Research. 67. 4473–4473.2 indexed citations
Andrews, Paul A., et al.. (2004). Interspecies comparison of the pharmacokinetics and metabolism of SAHA. Cancer Research. 64. 928–928.1 indexed citations
15.
Hockly, Emma, Victoria M. Richon, Donna L. Smith, et al.. (2003). Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proceedings of the National Academy of Sciences. 100(4). 2041–2046.667 indexed citations breakdown →
Kutko, Martha C., Richard D. Glick, Lisa M. Butler, et al.. (2001). The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid.. Adelaide Research & Scholarship (AR&S) (University of Adelaide). 61(9). 3591–4.129 indexed citations
18.
Münster, Pamela N., Tiffany A. Troso-Sandoval, Neal Rosen, et al.. (2001). The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.. PubMed. 61(23). 8492–7.302 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.